These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1772 related items for PubMed ID: 23706500

  • 1. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [Abstract] [Full Text] [Related]

  • 2. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H, Shah CP, Weber M, Heier JS.
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
    Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR.
    Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263
    [Abstract] [Full Text] [Related]

  • 6. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB.
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [Abstract] [Full Text] [Related]

  • 7. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J, Costa JM, Beato JN, Freitas-da-Costa P, Brandão E, Falcão MS, Falcão-Reis F, Carneiro ÂM.
    Ophthalmologica; 2015 Jul; 233(3-4):155-61. PubMed ID: 25896317
    [Abstract] [Full Text] [Related]

  • 8. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS, Muecke J.
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [Abstract] [Full Text] [Related]

  • 13. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 14. Initial utilization of aflibercept in exudative age-related macular degeneration.
    Cho H, Weber ML, Shah CP, Heier JS.
    Eur J Ophthalmol; 2014 Aug; 24(4):576-81. PubMed ID: 24706352
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [Abstract] [Full Text] [Related]

  • 17. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I, Gianniou C, Dirani A.
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [Abstract] [Full Text] [Related]

  • 18. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC, Brown DM, Maldonado ME, Croft DE.
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [Abstract] [Full Text] [Related]

  • 19. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C.
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [Abstract] [Full Text] [Related]

  • 20. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
    Thorell MR, Nunes RP, Chen GW, Doshi RR, Dugar J, George MK, Kim BT, Lowrance MD, Modi D, Nahas Z, Gregori G, Yehoshua Z, Feuer W, Rosenfeld PJ.
    Ophthalmic Surg Lasers Imaging Retina; 2014 Apr; 45(6):526-33. PubMed ID: 25423632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 89.